| Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals N Fandos, V Pérez-Grijalba, P Pesini, S Olmos, M Bossa, VL Villemagne, ... Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 8, 179-187, 2017 | 179 | 2017 |
| Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis JD Doecke, V Pérez-Grijalba, N Fandos, C Fowler, VL Villemagne, ... Neurology 94 (15), e1580-e1591, 2020 | 124 | 2020 |
| Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's … IMW Verberk, EO Misdorp, J Koelewijn, AJ Ball, K Blennow, JL Dage, ... Alzheimer's & Dementia 18 (8), 1484-1497, 2022 | 94 | 2022 |
| Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition SL Risacher, N Fandos, J Romero, I Sherriff, P Pesini, AJ Saykin, ... Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 11, 510-519, 2019 | 94 | 2019 |
| Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer’s disease M Izco, P Martinez, A Corrales, N Fandos, S Garcia, D Insua, M Montanes, ... Neuroscience 263, 269-279, 2014 | 45 | 2014 |
| Validation of immunoassay-based tools for the comprehensive quantification of Aβ 40 and Aβ 42 peptides in plasma V Pérez-Grijalba, N Fandos, J Canudas, D Insua, D Casabona, ... Journal of Alzheimer's Disease 54 (2), 751-762, 2016 | 30 | 2016 |
| Longitudinal evaluation of the natural history of amyloid-β in plasma and brain SC Burnham, N Fandos, C Fowler, V Pérez-Grijalba, V Dore, JD Doecke, ... Brain communications 2 (1), fcaa041, 2020 | 27 | 2020 |
| The global Alzheimer's Association round robin study on plasma amyloid β methods J Pannee, LM Shaw, M Korecka, T Waligorska, CE Teunissen, E Stoops, ... Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 13 (1 …, 2021 | 24 | 2021 |
| Optimized protocol for amyloid-β extraction from the brain M Izco, P Pesini, V Pérez-Grijalba, N Fandos, M Sarasa Journal of Alzheimer's Disease 34 (4), 835-839, 2013 | 16 | 2013 |
| Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline M Pascual-Lucas, JA Allué, L Sarasa, N Fandos, S Castillo, J Terencio, ... Alzheimer's Research & Therapy 15 (1), 1-14, 2023 | 14 | 2023 |
| Outstanding phenotypic differences in the profile of amyloid-β between Tg2576 and APPswe/PS1dE9 transgenic mouse models of Alzheimer’s disease JA Allué, L Sarasa, M Izco, V Pérez-Grijalba, N Fandos, M Pascual-Lucas, ... Journal of Alzheimer's Disease 53 (3), 773-785, 2016 | 12 | 2016 |
| Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst) 8: 179–187 N Fandos, V Pérez-Grijalba, P Pesini, S Olmos, M Bossa, VL Villemagne, ... | 6 | 2017 |
| Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloidβ Are Strongly Associated With Healthy Aging in the Oldest Old G Fernández-Eulate, A Alberro, M Muñoz-Culla, M Zulaica, M Zufiría, ... Frontiers in aging neuroscience 10, 380, 2018 | 4 | 2018 |
| Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. Alzheimers Dement (Amst). 2019; 11: 510–9 SL Risacher, N Fandos, J Romero, I Sherriff, P Pesini, AJ Saykin | 3 | |
| Safety, tolerability and immunogenicity of an active anti‐Aβ40 vaccine (ABvac40) in patients with amnestic mild cognitive impairment (A‐MCI) or very mild alzheimer’s disease … EP Molina, P Pesini, M Sarasa‐SanJose, I Marcos, AM Lacosta, JA Allué, ... Alzheimer's & Dementia 16, e045720, 2020 | 2 | 2020 |
| P4‐273: ASSOCIATION BETWEEN PLASMA Aβ LEVELS AND CEREBRAL AMYLOID AND TAU DEPOSITION SL Risacher, N Fandos, J Romero, I Sherriff, AJ Saykin, LG Apostolova Alzheimer's & Dementia 14 (7S_Part_29), P1551-P1551, 2018 | 2 | 2018 |
| AB1601 topline results–Phase 2 study of ABvac40 in patients with amnestic mild cognitive impairment (a‐MCI) or very mild Alzheimer’s Disease (Vm‐AD). E Molina, S Castillo, AM Lacosta, JA Allué, N Fandos, M Montañés, ... Alzheimer's & Dementia 18, e065633, 2022 | 1 | 2022 |
| ABTEST-IA: A NEW RELIABLE TOOL FOR THE QUANTIFICATION OF Aβ40 AND Aβ42 IN CSF N Fandos, J Romero, M Pascual-Lucas, D Alcolea, S Castillo Alzheimer's Association International Conference, 2022 | | 2022 |
| Stability of the novel blood‐based biomarkers under pre‐analytical sample handling conditions: Results of the SABB‐GBSC working group IMW Verberk, EO Misdorp, J Koelewijn, AJ Ball, K Blennow, JL Dage, ... Alzheimer's & Dementia 17, e055441, 2021 | | 2021 |
| The Aβ42/Aβ40 ratio in plasma is associated with amyloid‐PET status and rate of progression in individuals with subjective cognitive decline: The Fundació ACE Healthy Brain … I de Rojas, N Fandos, J Romero, P Pesini, M Marquié, JP Tartari, ... Alzheimer's & Dementia 16, e045780, 2020 | | 2020 |
